登录新浪财经APP 搜索【信披】查看更多考评等级 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 1． 于2024年8月29日至2025年4月22日期间买入ST葫芦娃股票，并且在2025年4月23日收盘时卖出 或仍持有的投资者； 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 2024年12月28日，ST葫芦娃（维权）发布公告称，公司于12月26日收到中国证监会下发的《立案告知 书》。公告显示：海南葫芦娃药业集团股份有限公司及公司董事长刘景萍因涉嫌信息披露违法违规，根 据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对公司和刘 景萍立案。 ST葫芦娃在公告中表示，目前，公司各项生产经营活动正常有序开展，在立案调查期间，公司将积极 配合中国证监会的相关调查工作。 上海百悦律师事务所牛彬律师表示，ST葫芦娃及其实控人因涉嫌信息披露违法违规被证监会立案，相 关受损投资者或可依法索赔。暂定，符合以下任一区间条件的亏损投资者，可发起索赔预登记：（葫芦 娃维权入口） 2． ...

Core Viewpoint - Hainan Huluwa Pharmaceutical Group Co., Ltd. is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, leading to potential civil compensation claims from affected investors [1][2][6]. Group 1: Company Announcement - On March 15, 2025, Huluwa announced that it received a notice of investigation from the CSRC due to alleged information disclosure violations by the company and its chairman, Liu Jingping [1][6]. - The CSRC previously issued an administrative regulatory decision on the same day, identifying inaccuracies in the financial disclosures of the 2023 annual report, including revenue and profit figures [6]. Group 2: Financial Data Correction - On April 29, 2025, Huluwa released a correction notice regarding prior accounting errors affecting the financial data in the 2023 annual report and the 2024 semi-annual, first quarter, and third quarter reports [1][6]. Group 3: Investor Compensation - Investors who purchased Huluwa's stocks or bonds between April 27, 2024, and March 14, 2025, and sold or continued to hold them after March 15, 2025, may register for compensation claims [2][6]. - The compensation scope includes investment differences, commissions, stamp duties, and interest losses due to the alleged fraudulent activities [2][6]. Group 4: Legal Proceedings - Investors are advised that while they can initiate lawsuits without an administrative penalty decision, the lack of such a decision may increase the risk of losing the case [3][7]. - The progress of civil compensation lawsuits may be affected by the company's potential delisting or bankruptcy proceedings [8].

Group 1 - Hubei Yihua has received acceptance from the Shenzhen Stock Exchange for its application to issue convertible bonds to unspecified objects [1] - Tongye Technology plans to acquire 91.69% of Beijing Silingke Semiconductor Technology Co., Ltd. for a total price of 561 million yuan [2] - Heng Rui Medicine has signed an exclusive licensing agreement with Hansoh Pharmaceutical, which includes a payment of 30 million yuan and potential milestone payments up to 190 million yuan [3] Group 2 - Jun Da Co. announced that its strategic cooperation framework agreement with Shangyi Optoelectronics will not significantly impact its current operating performance [4] - Jinchuan Group's wholly-owned subsidiary is jointly investing in a venture capital partnership to invest in Shanghai Gesi Information Technology Co., Ltd. [5] - Baili Tianheng plans to apply for the registration of debt financing tools not exceeding 10 billion yuan [6] Group 3 - Yuanda Environmental Protection announced the resignation of its chairman Chen Bin due to work changes [7] - Aerospace Development reported that its subsidiary's revenue accounted for less than 1% of the total revenue in the first three quarters of 2025 [8] - ST Huluwawa and its chairman Liu Jingping are under investigation by the China Securities Regulatory Commission for information disclosure violations [10] Group 4 - Jia Mei Packaging confirmed that it has no plans for significant changes to its main business or for a reverse merger in the next 36 months [11] - Wangfujing has won the bid for the duty-free project at Beijing Capital International Airport, with a guaranteed operating fee of 113 million yuan for the first year [12] - Siwei Liekong has suspended trading due to potential changes in control [13] Group 5 - Zhongchao Holdings announced a tax payment and late fee totaling 8.2881 million yuan [14] - Yongshuntai plans to conduct foreign exchange derivative trading with a total amount not exceeding 1.7 billion yuan in 2026 [15] - Guojin Securities has been approved to publicly issue company bonds not exceeding 25 billion yuan [16] Group 6 - Jincheng Pharmaceutical's subsidiaries are required to pay a total of 21.5968 million yuan in taxes and late fees [17] - China Shenhua's subsidiary has successfully completed the trial operation of its power generation unit [19] - Yijing Optoelectronics has received a hearing notice regarding the inability to advance its photovoltaic project [20] Group 7 - Jiga Development has received debt waivers totaling 378 million yuan from its controlling shareholder and related parties [21] - ST Lutong plans to apply to the Shenzhen Stock Exchange to revoke other risk warnings after a shareholder repaid funds [22] - Xin'ao Co. is progressing with the privatization of Xin'ao Energy and has completed significant asset restructuring foreign exchange registration [23]

新京报贝壳财经讯12月28日，海南葫芦娃药业集团股份有限公司(下称"ST葫芦娃（605199）")发布公告 称，公司及公司董事长刘景萍于2025年12月26日分别收到中国证券监督管理委员会下发的《立案告知 书》。因公司及公司董事长刘景萍涉嫌信息披露违法违规，根据《中华人民共和国证券法》《中华人民 共和国行政处罚法》等法律法规，中国证监会决定对公司和刘景萍立案。目前，公司各项生产经营活动 正常有序开展，在立案调查期间，公司将积极配合中国证监会的相关调查工作，并严格按照有关法律法 规及监管要求履行信息披露义务。 ...

Group 1: Company News - Shengyuan Environmental Protection's subsidiary incurred a loss of approximately 46.92 million yuan from a private equity investment, representing a decline of 81.54% in net value, exceeding 10% of the company's audited net profit for the last fiscal year [1] - CATL announced plans to widely apply sodium batteries in various sectors including battery swapping, passenger vehicles, commercial vehicles, and energy storage in 2026, indicating a new trend of "sodium-lithium dual stars" [3] - Yicheng Optoelectronics received a hearing notice regarding a 140 million yuan capital recovery due to failure to fulfill investment agreements for a solar project in Anhui Province [12] - ST Huluwawa is under investigation by the CSRC for suspected information disclosure violations, with the chairman facing scrutiny for failing to timely disclose performance forecasts [14] - Longjiang Pharmaceutical Holdings is facing administrative penalties for financial fraud, with a proposed fine of 10 million yuan for the company and 31 million yuan for 14 responsible individuals [15] - Hainan Huatie was fined 8 million yuan for incomplete disclosure of significant contract terms and failure to timely report contract changes [17] - Vanke A extended the grace period for the repayment of its 2022 mid-term notes to 30 trading days, allowing for potential resolution of the repayment issue [18] - Jiga Development received a debt waiver of 378 million yuan from its controlling shareholder and related parties, which is unconditional and irrevocable [19] - Kweichow Moutai plans to reduce the supply of high-value products in 2026 and will stop using distribution methods, aiming to stabilize prices [20] Group 2: Industry Dynamics - The scale of China's ETFs has surpassed 6 trillion yuan, marking a growth of over 60% from the beginning of the year, with 1,381 ETFs now available [6] - Four major lithium iron phosphate companies announced production cuts of 35%-50% in January 2026, affecting approximately 50% of the market share [7] - Demand for lithium batteries in the new energy vehicle sector showed significant weakness in November, with production growth of only 23% compared to a 13% increase in retail [9]

Core Viewpoint - ST HuLuWa has been officially investigated by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure regulations, which may indicate an escalation in regulatory scrutiny [2][12]. Group 1: Company Operations and Compliance - ST HuLuWa announced that its production and operational activities are currently normal and orderly, and the company will actively cooperate with the CSRC during the investigation [4][24]. - The company is a pharmaceutical manufacturer that integrates research, production, and sales, focusing on traditional Chinese medicine and chemical drugs across various treatment areas [4][24]. Group 2: Financial Reporting Issues - The Hainan Securities Regulatory Bureau found inaccuracies in ST HuLuWa's 2023 annual report regarding revenue and profit disclosures, leading to administrative corrective measures [4][29]. - The company reported significant corrections in its financial data: total revenue was adjusted from 1.905 billion to 1.795 billion, and net profit was revised down from 106.5 million to 10.85 million, reflecting a substantial decrease [8][29]. Group 3: Management Changes - Liu Jingping, the chairman, briefly resigned as the general manager to focus on strategic planning and governance, while Zhang Mingrui was appointed as the new general manager but resigned within two months for personal reasons [15][37]. - Liu Jingping was reappointed as the general manager on June 27, 2025, after the resignation of Zhang Mingrui [38].

Market Overview - The market structure characteristics are expected to continue in the short term, with trading volume being a key signal for market trends [1][9] - Major U.S. stock indices hovered near historical highs, with the Dow Jones down 0.04%, Nasdaq down 0.09%, and S&P 500 down 0.03% at the close [3] - The Nasdaq China Golden Dragon Index rose by 0.72%, with notable gains from Alibaba (1.5%), Pinduoduo (1.4%), and Baidu (1.2%) [3] Commodity Markets - Gold futures for December delivery increased by 1.08% to $4,529.10 per ounce, while silver futures surged by 7.68% to $76.48 per ounce, with post-market gains pushing silver above $78 per ounce [4] - International oil prices declined, with WTI crude down 2.76% to $56.74 per barrel and Brent crude down 2.57% to $60.64 per barrel [3] Financial Policies and Regulations - The People's Bank of China and the State Administration of Foreign Exchange announced the promotion of integrated currency pools for multinational companies, aiming to streamline cross-border fund management [6] - The National Bureau of Statistics released implementation opinions to strengthen data technology innovation, targeting the establishment of leading data technology innovation platforms by 2027 [6] Market Sentiment and Investment Trends - Institutional investors are increasingly adding to A500 ETF and other broad-based products, contributing to stable incremental capital in the market [9] - The market is currently characterized by a "buy on dips, structural switching" approach rather than aggressive trend-based accumulation at high levels, indicating a potential for gradual upward movement in the market [9] Company-Specific Developments - Xiaomi Group's co-founder plans to sell up to $2 billion of Class B common stock [10] - ST Houlv's chairman is under investigation for information disclosure violations by the China Securities Regulatory Commission [10] - Chipmaker AI orders from Chip Original Co. exceeded 24.94 billion yuan, with over 84% of fourth-quarter orders related to AI computing power [10]

Group 1 - ST HuLuWa and its chairman Liu Jingping are under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [1] - The company claims that its production and operational activities are currently normal and orderly [1] Group 2 - BaiLi TianHeng plans to apply for the registration and issuance of debt financing instruments to optimize its debt structure, with a proposed issuance scale not exceeding 10 billion RMB [2] - The company asserts that this initiative will promote high-quality, stable, and sustainable development, benefiting all shareholders without harming minority shareholders [2] Group 3 - PaiLin Bio's controlling shareholder has signed a supplementary agreement for share transfer, extending the final deadline for the transaction to June 30, 2026, due to ongoing state-owned enterprise and antitrust reviews [3] - The share transfer is subject to compliance confirmation from the Shenzhen Stock Exchange and other regulatory approvals [3] Group 4 - JinCheng Pharmaceutical's subsidiary is required to pay approximately 21.6 million RMB in back taxes and penalties for the years 2017 and 2018, which have now been settled [4] - The company plans to seek compensation from previous equity transfer parties, with a potential impact of approximately -9.93 million RMB on the net profit attributable to shareholders for the current period [4] Group 5 - HengRui Pharmaceutical has signed an exclusive licensing agreement with HanSen Pharmaceutical for the SHR6508 project, allowing HanSen to commercialize the product [5] - This agreement enables HengRui to focus resources on priority treatment areas and leverage commercial services to expedite market entry [5]

目前，公司各项生产经营活动正常有序开展，在立案调查期间，公司将积极配合中国证监会的相关调查 工作，并严格按照有关法律法规及监管要求履行信息披露义务。 公司指定信息披露媒体为《上海证券报》《中国证券报》《证券日报》《证券时报》和上海证券交易所 网站（www.sse.com.cn），公司相关信息均以公司在上述指定媒体披露的信息为准。敬请广大投资者理 性投资，注意投资风险。 特此公告。 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 海南葫芦娃药业集团股份有限公司（以下简称"公司"）及公司董事长刘景萍女士于2025年12月26日分别 收到中国证券监督管理委员会（以下简称"中国证监会"）下发的《立案告知书》（编号：证监立案字 0292025008号和证监立案字0292025009号）。因公司及公司董事长刘景萍女士涉嫌信息披露违法违规， 根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对公司和 刘景萍女士立案。 海南葫芦娃药业集团股份有限公司 董事会 2 ...

Market News - The Ministry of Finance announced that a more proactive fiscal policy will continue in 2026, focusing on expanding fiscal expenditure, optimizing government bond tools, enhancing transfer payment efficiency, and improving expenditure structure [3] - The National Bureau of Statistics will release the December PMI data on December 31, with November's manufacturing PMI at 49.2%, a slight increase of 0.2 percentage points from October [4] - The People's Bank of China aims to significantly increase the scale and proportion of various long-term funds invested in A-shares, promoting a virtuous cycle between capital market stability and high-quality economic development [6] - The Shanghai and Shenzhen Stock Exchanges announced a series of fee reduction measures for 2026, expected to save over 1.9 billion yuan in total [7] Sector Developments - The Ministry of Industry and Information Technology established a standardization committee for humanoid robots and embodied intelligence, focusing on key technologies and industry standards [11] - The 2025 Shenzhen Brain Conference aims to create a platform for industry integration and innovation [13] - The 2025 China Green Hydrogen Industry Conference will discuss policies and technological breakthroughs that will impact the green hydrogen industry chain [14] Individual Stock Events - CATL plans to apply sodium batteries on a large scale in various sectors including battery swapping and energy storage in 2026 [17] - Xiaomi's co-founder plans to reduce holdings of up to $2 billion in B-class common stock [17] - ST Huluwawa and its chairman are under investigation for information disclosure violations [17] Lock-up Expiration - A total of 34 companies will have lock-up shares released this week, amounting to 3.697 billion shares with a total market value of approximately 58.895 billion yuan [18] - The peak lock-up expiration date is December 30, with 13 companies releasing shares worth a total of 27.645 billion yuan [18] Institutional Outlook - CITIC Securities highlights that 39 out of 360 industry/theme ETFs reached new highs in December, with a focus on communication and resource-related ETFs [25] - Guojin Securities identifies new investment themes emerging in 2026, emphasizing the importance of AI investments and the recovery of global manufacturing [26] - Zhongtai Securities believes there is still upward potential in the market before the Spring Festival, with opportunities for low-cost positioning [27]